Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $510.00 at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price lowered by Needham & Company LLC from $529.00 to $510.00 in a report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on ALNY. Bank of America dropped their price objective on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Raymond James Financial restated an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Finally, Leerink Partners lowered their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $476.34.

Alnylam Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ:ALNY opened at $308.48 on Thursday. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The firm’s 50-day simple moving average is $377.85 and its 200-day simple moving average is $424.10. The company has a market cap of $40.75 billion, a price-to-earnings ratio of 1,285.33 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 26.61% and a net margin of 1.36%.The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the company earned ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 31,305 shares of company stock worth $12,459,785 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ALNY. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $27,000. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $30,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: AMVUTTRA is now a major revenue driver: Alnylam highlighted the U.S. approval for AMVUTTRA in ATTR‑CM and reported nearly $3.0B in total net product revenues for 2025 (about +81% y/y), which management says powered the breakout year and provides clear product momentum. Business Wire: Q4 & Full-Year 2025 Results
• Positive Sentiment: Management framed the quarter as a breakout and guided to multi‑billion dollar revenue expectations for 2026, which some bullish analysts interpret as confirmation of strong growth trajectory. TipRanks: Growth After Breakout Year
• Neutral Sentiment: FY‑2026 revenue guidance was given as a range (roughly $5.3B–$5.8B versus consensus near $5.5B), leaving room for upside or downside depending on product uptake and launches — this reduced precision is creating investor uncertainty. (See company release above.)
• Neutral Sentiment: Coverage and metrics reporting are mixed: some outlets (Zacks, Seeking Alpha) flagged an EPS/revenue beat on certain adjusted measures, while other summaries emphasize misses on consensus figures — investors should check the company slide deck and the call for GAAP vs. non‑GAAP reconciliation. Zacks: Key Metrics on Q4 Seeking Alpha: Earnings Presentation
• Negative Sentiment: Some market writeups highlighted a headline EPS/revenue shortfall versus certain consensus estimates, and that framing appears to have driven intraday selling pressure. That commentary (and any GAAP/adjustment confusion) likely explains today’s share weakness. Fool: Why ALNY Slipped
• Negative Sentiment: An analyst at Needham trimmed the price target from $529 to $510 (still a buy), a modest downgrade that removes some upside perception and may contribute to near‑term pressure. Benzinga: Price Target Update

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.